Lung cancer:intragenic ERBB2 kinase mutations in tumours

Stephens, Philip, Hunter, Chris, Bignell, Graham, Edkins, Sarah, Davies, Helen, Teague, Jon, Stevens, Claire, O'meara, Sarah, Smith, Raffaella, Parker, Adrian, Barthorpe, Andy, Blow, Matthew, Brackenbury, Lisa, Butler, Adam, Clarke, Oliver, Cole, Jennifer, Dicks, Ed, Dike, Angus, Drozd, Anja, Edwards, Ken, Forbes, Simon, Foster, Rebecca, Gray, Kristian, Greenman, Christopher, Halliday, Kelly, Hills, Katy, Kosmidou, Vivienne, Lugg, Richard, Menzies, Andy, Perry, Janet, Petty, Robert, Raine, Keiran, Ratford, Lewis, Shepherd, Rebecca, Small, Alexandra, Stephens, Yvonne, Tofts, Calli, Varian, Jennifer, West, Sofie, Widaa, Sara, Yates, Andrew, Brasseur, Francis, Cooper, Colin S., Flanagan, Adrienne M., Knowles, Margaret, Leung, Suet Y., Louis, David N., Looijenga, Leendert H. J., Malkowicz, Bruce, Pierotti, Marco A., Teh, Bin, Chenevix-trench, Georgia, Weber, Barbara L., Yuen, Siu T., Harris, Grace, Goldstraw, Peter, Nicholson, Andrew G., Futreal, P. Andrew, Wooster, Richard and Stratton, Michael R. (2004) Lung cancer:intragenic ERBB2 kinase mutations in tumours. Nature, 431 (7008). pp. 525-526. ISSN 0028-0836

Full text not available from this repository. (Request a copy)

Abstract

The protein-kinase family is the most frequently mutated gene family found in human cancer and faulty kinase enzymes are being investigated as promising targets for the design of antitumour therapies. We have sequenced the gene encoding the transmembrane protein tyrosine kinase ERBB2 (also known as HER2 or Neu) from 120 primary lung tumours and identified 4% that have mutations within the kinase domain; in the adenocarcinoma subtype of lung cancer, 10% of cases had mutations. ERBB2 inhibitors, which have so far proved to be ineffective in treating lung cancer, should now be clinically re-evaluated in the specific subset of patients with lung cancer whose tumours carry ERBB2 mutations.

Item Type: Article
Uncontrolled Keywords: carcinoma, non-small-cell lung,dna mutational analysis,enzyme activation,humans,lung neoplasms,models, molecular,mutation,neoplasms,protein structure, tertiary,quinazolines,receptor, epidermal growth factor,receptor, erbb-2
Faculty \ School: Faculty of Medicine and Health Sciences > School of Rehabilitation Sciences
Faculty of Science > School of Computing Sciences

University of East Anglia > Faculty of Science > Research Groups > Computational Biology (subgroups are shown below) > Analysis and models of genomic variation
Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User: Pure Connector
Date Deposited: 20 Jan 2014 16:02
Last Modified: 10 Jun 2020 00:03
URI: https://ueaeprints.uea.ac.uk/id/eprint/46163
DOI: 10.1038/431525b

Actions (login required)

View Item View Item